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During the acute phase of Trypanosoma cruzi infection, macrophages can act as 
host cells for the parasites as well as effector cells in the early anti-parasitic immune 
response. Thus, the targeting of specific signaling pathways could modulate macro-
phages response to restrict parasite replication and instruct an appropriate adaptive 
response. Recently, it has become evident that Wnt signaling has immunomodulatory 
functions during inflammation and infection. Here, we tested the hypothesis that during 
T. cruzi infection, the activation of Wnt signaling pathway in macrophages plays a role in 
modulating the inflammatory/tolerogenic response and therefore regulating the control 
of parasite replication. In this report, we show that early after T. cruzi infection of bone 
marrow-derived macrophages (BMM), β-catenin was activated and Wnt3a, Wnt5a, 
and some Frizzled receptors as well as Wnt/β-catenin pathway’s target genes were 
upregulated, with Wnt proteins signaling sustaining the activation of Wnt/β-catenin 
pathway and then activating the Wnt/Ca+2 pathway. Wnt signaling pathway activation 
was critical to sustain the parasite’s replication in BMM; since the treatments with spe-
cific inhibitors of β-catenin transcriptional activation or Wnt proteins secretion limited 
the parasite replication. Mechanistically, inhibition of Wnt signaling pathway armed 
BMM to fight against T. cruzi by inducing the production of pro-inflammatory cytokines 
and indoleamine 2,3-dioxygenase activity and by downregulating arginase activity. 
Likewise, in vivo pharmacological inhibition of the Wnts’ interaction with its receptors 
controlled the parasite replication and improved the survival of lethally infected mice. 
It is well established that T. cruzi infection activates a plethora of signaling pathways 
that ultimately regulate immune mediators to determine the modulation of a defined 
set of effector functions in macrophages. In this study, we have revealed a new sig-
naling pathway that is activated by the interaction between protozoan parasites and 
host innate immunity, establishing a new conceptual framework for the development 
of new therapies.
Keywords: Trypanosoma cruzi infection, Wnt proteins, beta-catenin, macrophages, cytokines, indoleamine 
2,3-dioxygenase
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inTrODUcTiOn
Chagas’ disease, caused by the protozoan parasite Trypanosoma 
cruzi, represents a major cause of heart disease and cardiovascular-
related deaths in endemic areas and causes a significant economic 
burden on the affected countries. Approximately 8 million people 
are infected with T. cruzi in Central and South America, and at 
least 120 million are at risk of infection (1). Currently, there are 
no vaccines available to prevent Chagas disease, and treatment 
options are limited to anti-parasitic drugs that are expensive, not 
well tolerated, and effective only during short periods of the acute 
phase (2).
The entry of metacyclic trypomastigotes (Tps) of T. cruzi into 
the mammalian host initiates the invasion by these parasites of 
several host cell types where they are converted into amastigotes, 
which are the replicative form of this parasite (3). During the 
acute phase of the infection macrophages represent an important 
target of Trypanosoma cruzi and therefore, these cells are central 
for the control of this pathogen. Within macrophages, the replica-
tion of T. cruzi can be either inhibited or favored leading to the 
dissemination of the parasite (4). Thus, it has been reported that 
during the early phase of infection, the control T. cruzi parasitism 
is dependent on macrophage activation through toll-like recep-
tors (TLRs) and their subsequent activation by pro-inflammatory 
cytokines. Activated macrophages  upregulate inducible nitric 
oxide synthase (iNOS) and indoleamine 2,3-dioxygenase (IDO) 
enzymes, leading to the production of nitric oxide (NO) and 
kynurenines, with both being important effector molecules that 
induce death of the amastigotes (5–9). The protective mecha-
nisms of cell-mediated immunity (Th1  cells) are required for 
the resistance during this infection; nevertheless, unbalanced 
Th1 cells can also orchestrate a deleterious response that can 
cause tissue damage and fibrosis, since high levels of NO, IFN-γ, 
and tumor necrosis factor (TNF) have been associated with the 
pathogenesis of chronic Chagas disease (10–14). Therefore, a 
better understanding of the cellular and molecular mechanisms 
that orchestrate the different signals that promote the effective 
macrophage activation (able to restrict parasite replication) fol-
lowed by its opportune contraction to prevent immunopathology 
is mandatory to design improved therapeutic strategies.
The Wnt pathway is an evolutionarily highly conserved signal-
ing system that plays a critical role in cellular development, moti-
lity, polarization, survival, and proliferation (15, 16). In the last years, 
emerging studies have highlighted that the Wnt signaling pathway, 
particularly in dendritic cells (DC) and macrophages, plays a major 
role in regulating tolerance versus immunity. Members of the Wnt 
family are lipid-modified glycoproteins secreted by different cell 
types that bind to G-protein-coupled receptors of the Frizzled 
(Fzd) family and different coreceptors to activate a signaling cas-
cade involved in complex mechanisms of gene regulation. In mice 
and human, 19 ligands secreted glycoproteins of the Wnt family, 10 
seven-transmembrane receptors of the Fzd family, as well as several 
coreceptors or alternative receptors are known (16, 17). Depending 
on the composition of the Wnt–Fzd-coreceptor complex and the 
cellular context, Wnt proteins can initiate at least three different 
intracellular signaling cascades that regulate many cellular events: 
the Wnt/β-catenin called canonical pathway, the Wnt/Planar cell 
polarity pathway, and the Wnt/Ca+2 pathway (18, 19). In resting 
state, cytosolic/nuclear β-catenin is maintained at a very low level 
through rapid turnover of free β-catenin. This turnover is executed 
through a multi-protein complex, termed the β-catenin destruc-
tion complex, integrated by AXIN1/2, adenomatous polyposis 
coli, casein kinase I-alpha, and glycogen synthase kinase 3 beta 
(GSK-3β). GSK-3β sequentially phosphorylates β-catenin with 
β-catenin hyperphosphorylated subjected to ubiquitination and 
proteasomal degradation. Activation of Wnt/β-catenin signaling 
pathway results in the inhibition of the activity of GSK-3β, which 
leads to the accumulation of β-catenin in the cytoplasm and its 
translocation to the nucleus, where it interacts with T-cell factor/
lymphoid enhancer factor family members and regulates the 
transcription of several target genes (16, 17). While canonical 
Wnt signaling has been extensively studied from the view point 
of innate and adaptive immune response, the non-canonical Wnt/
Ca+2 signaling cascade has been less focused on. The binding of Wnt 
ligand to cognate Fzd receptor leads to the activation of calcium/
calmodulin-dependent kinase II (CaMKII) and protein kinase C 
(PKC). Both CaMKII and PKC activate many nuclear transcription 
factors as NF-κB and CREB. Similarly, calcium ions can activate 
widely expressed protein phosphatase calcineurin that can activate 
cytoplasmic protein nuclear factor associated with T cells (NFAT) 
via dephosphorylation. This event results in accumulation, nuclear 
translocation and transcription of several NFAT target genes, 
including pro-inflammatory genes in lymphocytes (20).
Human and murine DC and macrophages express various 
receptors and Wnt proteins and are susceptible to both  canonical 
and non-canonical signaling, and recently, several studies have 
emphasized the important role of DC and macrophages Wnt/β-
catenin pathway in regulating inflammatory responses to micro-
bial infections (21, 22). In DC, the activation of canonical and 
Wnt/Ca+2 pathways is associated with the development of a tolero-
genic profile, secretion of anti-inflammatory cytokines, induction 
of Treg cells, and the inhibition of the adaptive immune response 
(23–28). However, Wnt pathways activation in macrophages 
may have both pro- and anti-inflammatory consequences,  and 
different Wnt proteins may effectively cross-regulate each 
other in macrophages [reviewed in Ref. (21, 29)]. Wnt proteins 
and Fzd receptors are induced by STAT3-, TLR2-, TLR4-, and 
NF-κB-mediated signaling and, in addition to direct activation 
of β-catenin by Wnt proteins, TLR-mediated signals can also 
directly activate β-catenin (21, 26, 28, 30–37). Considering that 
TLR2 and TLR4 are involved in the recognition of different 
T. cruzi components (38–40), here we tested the hypothesis 
that during T. cruzi infection, the activation of Wnt signaling 
pathway in macrophages plays a role modulating the inflamma-




All animal experiments were approved by and conducted 
in accordance with guidelines of the Animal Care and Use 
Committee of the Facultad de Ciencias Químicas, Universidad 
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Nacional de Córdoba (Approval Number HCD 831/15). C57BL/6 
(B6) was obtained from School of Veterinary, La Plata National 
University (La Plata, Argentina). All animals were housed in the 
Animal Facility of the Facultad de Ciencias Químicas, Universidad 
Nacional de Córdoba (OLAW Assurance number A5802-01). 
The Tulahuen strain of T. cruzi was used, which was maintained 
by weekly i.p. inoculations in mice.
reagents
Macrophages were cultured in complete medium: RPMI 1640 
(Gibco, ThermoFisher Scientific) supplemented with 2  mM 
GlutaMAX (Gibco, ThermoFisher Scientific), 10% heat- inactivated 
fetal calf serum (Gibco, Thermo Fisher), and 50 µg/mL Gentamicin 
(Gibco, ThermoFisher Scientific). PBS was purchased from Gibco 
(ThermoFisher Scientific); bovine serum albumin and DMSO 
were obtained from Sigma-Aldrich.
cells
Bone marrow-derived macrophages (BMM) were generated as 
described previously (41). Peritoneal macrophages (PM) were 
obtained as described previously (42). J774 murine macrophages 
and the human monocytic THP-1 cell lines were obtained from 
the American Type Culture Collection (Manassas, VA, USA). 
THP-1 cell line was differentiated into macrophages by culture 
in complete medium supplemented with of 50  nM phorbol 
12-myristate 13-acetate (Sigma-Aldrich) for 24  h followed by 
24 h of incubation in complete medium.
In Vitro infections and Treatments
Mo were incubated with LiCl (10 mM, #746460 Sigma-Aldrich), 
BIO (5 µM, #3194 TOCRIS), iCRT14 (50 µM, #4299, TOCRIS), 
CCT036477 (20 µM, #BML-WN114, ENZO), IWP-L6 (20 µM, 
#504819, Calbiochem), IFN-γ (10  ng/mL, Sigma-Aldrich) plus 
LPS (10 µg/mL, from Escherichia coli serotype 0111:B4, Sigma-
Aldrich), 1-methyl-d-tryptophan (1-MT, #860646, Sigma-
Aldrich) or complete medium before being infected with T. cruzi 
Tps (Mo:Tps = 1:3). Culture medium with PBS or DMSO was used 
as vehicle control for LiCl and 1-MT or iCRT14, CCT036477, and 
IWP-L6, respectively. MeBIO (5 µM, #3873, TOCRIS) was used 
as control of BIO.
In Vitro Trypanocidal activity assay
The growth of parasites in Mos was evaluated by counting the 
intracellular amastigotes by immunofluorescence assay using 
serum of patient with chronic Chagas disease as described previ-
ously (8). The number of intracellular amastigotes was calculated 
by dividing intracellular parasites (n/200 cells) in differentially 
treated cultures by number of intracellular parasites (n/200 cells) 
in the corresponding vehicle-treated cultures, and expressed as 
relative units.
Western Blotting
Spleen cells or BMM treated with RIPA buffer were analyzed by 
10% SDS-PAGE and transferred to a nitrocellulose membrane. 
After blocking with 5% milk the membranes were incubated with 
the following antibodies: anti-β-catenin (15B8, eBioscience), 
anti-p-Ser552-β-catenin (D8E11, Cell Signaling), anti-NFATc1 
(7A6, Santa Cruz Biotechnology), anti-p-Thr286-CaMKII (D21E4, 
Cell Signaling), anti-p-Ser9-GSK-3β (37F11, Cell Signaling), 
anti-Wnt3a (ab19925-100 polyclonal, Abcam), anti-Wnt5a 
(ab72583 polyclonal, Abcam), anti-IDO antibody (Santa Cruz 
 Biotechno logy) followed by anti-rabbit or -mouse fluor-coupled 
secondary antibody. Anti-β-actin (mAbcam8226, Abcam) was 
used as loading control. The blots were revealed by incubation 
with corresponding IRD Fluor 800-labeled IgG or IRD Fluor 
680-labeled IgG secondary antibody (LI-COR Inc., Lincoln, NE, 
USA) for 1 h at room temperature. After washing, the membranes 
were scanned with the Odyssey infrared imaging system (LI-COR, 
Lincoln, NE, USA) at a wavelength of 700–800 nm. Densitometric 
analysis was performed using ImageJ software.
β-catenin and nFaTc1 
immunofluorescence
The cells were fixed in 4% formaldehyde and perm with 10% 
TritonX-100 for 15 min, washed three times with 0.01 M PBS, 
and incubated with 5% bovine serum albumin (Sigma-Aldrich) 
for 1 h for blocking. The sections were then incubated overnight 
at 4°C with anti-β-catenin (15B8, eBioscience) or anti-NFATc1 
(7A6, Santa Cruz Biotechnology) primary antibodies. Next, the 
cells were washed three times with 0.01 M PBS, incubated with 
secondary antibody Alexa Fluor 488-conjugated Goat anti-Mouse 
IgG (#A11001, Invitrogen) for 4 h and washed three times with 
0.01 M PBS. For nuclear counterstaining, the cells were incubated 
with 4′,6-diamidino-2-phenylindone (Cell Signaling Technology, 
#4083) for 10 min, washed in 1× PBS, and the slides were set with 
FluorSave™ reagent (EMD Millipore). Expression and localiza-
tion of beta-catenin were observed with an Olympus FV1200 
laser scanning confocal microscope (Olympus Corporation) with 
fixed exposure time for all samples. Colocalization was quantified 
as a ratio of overlapping pixels to the total number of pixels by 
Threshold Mander’s coefficient and expressed as nuclear percent-
age (% nuclear). The preparations were visualized using confocal 
microscopy (Olympus FV1200), and the analyses of images were 
carried out using FIJI/ImageJ.
Measurement of cytokine Production
Cytokines were measured in culture supernatants of BMM 24 h 
post-infection (pi) by capture ELISA using antibodies and proto-
cols suggested by the manufacturer (eBioscience). The cytokine 
concentration was expressed as index of cytokine release (Index) 
obtained by dividing the cytokine release of inhibitors/activators-
treated BMM by the cytokine release of vehicle-treated BMM.
Quantitative real-Time-Pcr (q-Pcr)
RNA was extracted from BMM by the Trizol reagent (Invitrogen, 
ThermoFisher Scientific) and reverse-transcribed into cDNA 
by using Revert Aid First Strand cDNA Synthesis (Fermentas). 
Transcripts were quantified by real-time quantitative PCR on 
an StepOnePlus™ Real-Time System (ThermoFisher Scientific) 
using SYBR Green (ThermoFisher Scientific) with the following 
primers (all primers listed in the 5′ to 3′ orientation): Wnt3a TTC 
TTA CTT GAG GGC GGA GA (forward) and CTG TCG GGT 
CAA GAG AGG AG (reverse); Wnt5a GCA GGA CTT TCT CAA 
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GGA CA (forward) and CCC TGC CAA AGA CAG AAG TA 
(reverse); Ctnnb1 AGC CGA GAT GGC CCA GAA T (forward) 
and AAG GGC AAG GTT TCG AAT CAA (reverse); Ccnd1 AGT 
GCG TGC AGA AGG AGA TT (forward) and CAC AAC TTC 
TCG GCA GTC AA (reverse); Axin1 CTG GGC TTG TAT CCC 
ACT GT (forward) and ACC AAG CTG GTG GCT AGA GA 
(reverse); Wisp1 CTG GAC AGA AAA GGG CAT GT (forward) 
and AGG AAG GAG GGG AAA TCT CA (reverse); Fzd4 CTG 
CAG CAT GCC TAA TGA GA (forward) and CGT CTG CCT 
AGA TGC AAT CA (reverse); Fzd6 TCC GAC GCT TGA AGA 
AAA CT (forward) and CAA CCC CAG GTC CTC AAG TA 
(reverse); Fzd8 GCA GCA TGT TCG CTA TGA AA (forward) 
and AGT AGC CTG CTA TGG CCT CA (reverse); Fzd9 AGA 
GCC TGT GCT ACC GAA AA (forward) and CAA GGA GGG 
AGC AAC CAT AA (reverse); Actb CGC CAC CAG TTC GCC 
ATG GA (forward) and TAC AGC CCG GGG AGC ATC GT 
(reverse). Relative expression was normalized to β-actin (Actb) 
and expressed as mRNA relative levels. The cycling conditions 
included a hot start at 95°C for 10  min, followed by 40 cycles 
at 95°C for 15 s and 60°C for 1 min. Specificity was verified by 
melting curve analysis and agarose gel electrophoresis.
arginase and iDO activity
Arginase and IDO assays were performed as described previously 
(8, 43) with cell lysates that had been cultured in different condi-
tions as indicated in the figure legends.
nO assay
The production of NO was measured indirectly by assaying 
nitrites in the culture supernatant using the Griess reaction as 
described previously (8).
lactate Dehydrogenase (lDh) assay
Lactate dehydrogenase release was measured in the supernatant 
of BMM using LDH colorimetric assay kit (Wiener Lab) follow-
ing the manufacturer’s protocol and expressed as international 
units (I/U).
iWP-l6 Treatment
Groups of 6 mice (6–8 weeks old) maintained under standard 
conditions were infected with 5,000 bloodstream T. cruzi Tps 
by the i.p. route. On days 5, 8, 11, and 14 pi, mice were treated 
with IWP-L6 (7.5 mg/kg/dose) by the i.p. route. We resuspended 
IWP-L6 in DMSO (10  mg/mL) and then injected diluted in 
PBS, with this vehicle also being employed as a negative con-
trol. The levels of parasitemia were monitored every 2 days as 
described earlier, and the number of deaths was recorded daily. 
Determination of tissue parasitism was assessed in heart and 
liver obtained from 180-day-infected IWP-L6 or control mice as 
described previously (7).
statistical analysis
Statistical analyses were performed using Student’s t-test, and 
two-way ANOVA followed by Bonferroni’s post-test for compar-
ing more than two groups. The Kaplan–Meier analysis test was 
used for comparing survival of control and treated mice. Percent 
survival at each time was also compared by using the log-rank 
and Gehan–Breslow–Wilcoxon tests. The results were considered 
significantly different when P < 0.05.
resUlTs
T. cruzi infection Promotes Wnt signaling 
Pathway activation in spleen cells
Trypanosoma cruzi-infected B6 mice have great difficulty in con-
trolling inflammatory response, resulting in the premature death 
of these animals by liver failure. Interestingly, we have observed 
that B6, unlike BALB/c mice, did not expand the population of Treg 
cells in parallel with the large expansion undergone by the T cell 
compartment resulting in an increased ratio of T effector/Treg cells 
(not shown). These results suggest that, as observed in patients 
with severe chronic Chagas disease cardiomyopathy (12, 44), 
the fatal outcome in B6 mice may be linked to an unbalanced 
inflammatory response. For that, although in T. cruzi-infected B6 
mice the main target organ of pathological inflammatory response 
is the liver, and not the heart as in infected human patients, we 
performed the experiments in B6 mice to evaluate both parasite 
replication and inflammatory pathology.
To study whether experimental infection with T. cruzi induces 
the production of Wnt pathway proteins, the expression of the 
most common inflammation-linked Wnt proteins such as Wnt3a 
and Wnt5a, and β-catenin was evaluated in spleen cells from 
infected B6 mice at different times pi. Figure  1 shows that, as 
T. cruzi infection progresses, the expression of Wnt3a, Wnt5a, 
and β-catenin is positively regulated in spleen cells. These results 
suggest that T. cruzi recognition induces in spleen cells the 
expression of Wnt proteins that could signal for the activation 
of the Wnt/β catenin canonical pathway, taking into account the 
accumulation of β-catenin.
T. cruzi infection induces expression 
of Wnt Proteins and Fzd receptors 
in Macrophages
To evaluate whether T. cruzi experimental infection induces the 
expression of proteins involved in Wnt signaling in macrophages, 
BMM were in vitro infected with T. cruzi Tps and the expression of 
Wnt3a and Wnt5a transcripts and proteins determined by q-PCR 
and Western blot. Figures 2A,B show that in vitro infection of 
BMM with T. cruzi induced the expression of Wnt5a and Wnt3a 
transcripts and proteins. The evaluation by means of q-PCR of 
the transcripts corresponding to Fzd receptors that most strongly 
interact with Wnt3a and Wnt5a, such as Fzd4, Fzd6, Fzd8, and 
Fzd9 (45), revealed that as early as 5 min pi, there is an increase 
in the transcription of these genes (Figure 2C), suggesting that 
after the recognition of T. cruzi by innate immune receptors start 
the transcription of Wnt proteins that could signal through Fzd 
receptors to activate the Wnt signaling pathways.
T. cruzi infection induces First β-catenin 
activation and Then activates Wnt/ca+2 
Pathway in Macrophages
To evaluate whether T. cruzi infection activates β-catenin in BMM, 
the kinetics of expression of β-catenin (mRNA and protein) and 
FigUre 2 | In vitro Trypanosoma cruzi infection induces expression of Wnt proteins, Frizzled (Fzd) receptors, and β-catenin macrophages. Bone marrow-derived 
macrophages were in vitro infected with T. cruzi trypomastigotes or left uninfected (NI) and then evaluated for expression of Wnt proteins and Fzd receptors at 
different times post-infection (pi). (a) Expression of Wnt3a and Wnt5a mRNA (relative to β-actin) was determined by quantitative real-time-PCR. (B) The relative 
abundance of Wnt3, Wnt5a, and β-actin in the cell lysates were determined by Western blot and densitometry at 12 h pi. Representative Western blot and the 
ratio of Wnt3a or Wnt5a to β-actin are shown. (c) Expression of Fzd4, Fzd8, Fzd9, and Fzd6 mRNA (relative to β-actin) was determined by q-PCR. The results 
are expressed as the average of three independent experiments ± SEM. Abbreviation: AU, arbitrary units (*P < 0.05 and **P < 0.01).
FigUre 1 | Experimental Trypanosoma cruzi infection induces the expression of Wnt pathway proteins. Western blot analysis of Wnt3a, Wnt5a, and β-catenin 
expression in spleen mononuclear cell homogenates derived from uninfected (NI) or T. cruzi-infected B6 mice at different times post-infection. Images show 
one representative NI and one infected mice by time point. Each bar represents the mean ± SEM of protein relative expression levels quantified by scanning 
the intensity of bands areas in the homogenates normalized to β-actin (n = 5 mice per time point) (*P < 0.05; **P < 0.01; and ***P < 0.001).
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its translocation to the nucleus were evaluated in in vitro-infected 
BMM at different times pi. At very short times after the infec-
tion (5  min), a significant increase in the transcription of the 
gene coding for β-catenin (Ctnnb1) was detected (Figure  3A), 
while the protein expression and translocation to the nucleus 
began at 2 h pi and reached the maximum between 8 and 12 h 
pi (Figures 3A,B). Moreover, the upregulation of Wnt/β-catenin 
pathway-target genes transcription, such as Wisp1, Axin1, and 
Ccnd1, correlates with β-catenin accumulation and nucleus 
translocation (Figure 3C). In addition, accumulation of β-catenin 
was observed in PM from B6-infected mice obtained at 24 h pi 
(Figure 3D). Taken together, our results showed that in vitro and 
in vivo T. cruzi infection was associated with significant activation 
of the genes and proteins involved in the canonical Wnt signaling 
pathway in macrophages.
Next, we tested whether T. cruzi infection is also able to  activate 
Wnt/Ca+2 pathway by analyzing the expression of CaMKII phos-
phorylated at Thr286 [phosphorylated CAMKII (p-CAMKII)] 
and the activation and nuclear translocation of NFATc1. 
As shown in Figure 4A, T. cruzi infection led to an increase in 
the phosphorylation of CaMKII at Thr286 from 12 h pi. We also 
detected an induced NFATc1 activation after 18 h pi as measured 
FigUre 3 | Trypanosoma cruzi infection induces early β-catenin activation in macrophages. Bone marrow-derived macrophages were in vitro infected with 
trypomastigotes of T. cruzi or left uninfected (NI) and then evaluated for β-catenin activation. (a) mRNA and protein expression levels of β-catenin by q-PCR and 
Western blot at different times post-infection (pi). β-Catenin mRNA relative to β-actin is shown. A representative Western blot and the ratio of β-catenin to β-actin 
are shown. The results are expressed as the average of three independent experiments ± SEM. Abbreviation: AU, arbitrary units. (B) Expression and localization 
of β-catenin by immunofluorescence and confocal microscopy. (c) mRNA relative expression of β-catenin target genes Axin1, Wisp1, and Ccnd1 by q-PCR. mRNA 
expression levels normalized over the expression of β-actin are expressed as the average of three independent experiments ± SEM. (D) Peritoneal macrophages 
were obtained from uninfected or infected mice at 24 h pi, and the levels of expression and localization of β-catenin were evaluated by immunofluorescence and 
confocal microscopy. In panels (B,D), a representative field for each group is shown [(B,D), 1,200×]. Nuclear staining was detected with 4′,6-diamidino-2-
phenylindone (DAPI), and the levels of expression of β-catenin (% of total area) and the threshold Mander’s colocalization (% nuclear) coefficients calculated using 
FIJI/ImageJ program as described in Section “Materials and Methods.” Green, β-catenin; red, DAPI (*P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001).
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by faster migrating, dephosphorylated, active NFATc1 bands on 
Western blot (arrows; Figure 4B) and the increased expression 
and nuclear translocation of NFATc1 detected by immunofluores-
cence (Figure 4C). Interestingly, the upregulation of p-CaMKII 
and activation of NFATc1 were dependent on the secretion of Wnt 
proteins; since the use of IWP-L6, a porcupine inhibitor that is the 
O-acetyltransferase membrane involved in the palmitoylation of 
Wnt proteins, a critical modification for its secretion, was able 
to inhibit both p-CaMKII upregulation and NFATc1 activation 
(Figures 4D,E). Treatment of BMM with the calcium ionophore 
ionomycin was used as positive control of Ca+2 pathway activation 
(46). Moreover, we were unable to detect NFATc1 upregulation or 
translocation to the nucleus in PM obtained at 24 h pi (Figure S1 
in Supplementary Material), even though it’s upregulation was 
evident in PM obtained from infected mice at 18 days pi (Figure 
S2 in Supplementary Material).
The inhibition of Wnt/β-catenin signaling 
Pathway limits the replication of  
T. cruzi in Macrophages
To evaluate the role of the Wnt/β-catenin pathway activation 
in the control of T. cruzi intracellular replication, BMM were 
pretreated with LiCl or BIO, both inhibitors of GSK-3β activity 
which mimics activation of Wnt/β catenin signaling, or specific 
inhibitors of β-catenin-responsive transcription such as iCRT14 
and CCT036477 for 24 h before being infected. Then, the intracel-
lular amastigotes were counted by IF assay, with the results shown 
in Figures  5A,B. Treatment of BMM with IFN-γ plus LPS was 
used to activate BMM to control T. cruzi replication as described 
previously (8). β-Catenin-responsive transcription blockade with 
iCRT14 and CCT036477 was shown to result in a strong inhibi-
tory effect on intracellular parasite growth. Similar results were 
obtained by inhibiting the secretion of Wnt proteins with IWP-L6 
(Figures 5A,B). The inhibition of parasite replication observed by 
β-catenin transcription blockade was even more significant than 
those observed after the activation of BMM with IFN-γ plus LPS, 
and these results were not due to drugs-induced cytotoxicity, as 
revealed by using LDH release assay to determine cell membrane 
integrity (Figure  5C). In addition, the treatment with IWP-L6 
inhibited both β-catenin accumulation and nucleus translocation 
at 12 h pi (Figure 5D). Similar results were obtained when the drugs 
were added to the culture at the same time as the parasites (not 
shown). Likewise, inhibition of Wnt/β-catenin pathway or Wnt pro-
tein secretion in human monocyte-derived THP-1 macrophages 
and J774 cell line (macrophages derived from BALB/c mice) resulted 
in the suppression of intracellular parasite replication (Figure S3 
in Supplementary Material). On the other hand, treatments with 
β-catenin activators (LiCl and BIO) were unable to significantly 
increase the intracellular parasite growth (Figures 5A,B).
FigUre 4 | Trypanosoma cruzi infection induces late Wnt/Ca+2 pathway activation in macrophages. Bone marrow-derived macrophages were in vitro infected 
with trypomastigotes (Tps) of T. cruzi or left uninfected (NI) and then evaluated for calcium/calmodulin-dependent kinase II (CaMKII) phosphorylated at Thr286 
expression and NFATc1 expression and localization at different times post-infection (pi). Phosphorylated CAMKII (p-CAMKII) expression (a) and NFATc1 
expression (B) were assessed by Western blot and normalized to β-actin. (c) Expression and localization of β-catenin by immunofluorescence and confocal 
microscopy. A representative field for each group is shown (1,200×). Nuclear staining was detected with 4′,6-diamidino-2-phenylindone (DAPI), and the levels 
of expression of NFATc1 (% of total area) and the threshold Mander’s colocalization (% nuclear) coefficients calculated using FIJI/ImageJ program as described 
in Section “Materials and Methods.” Green, NFATc1; red, DAPI. (D,e) Bone marrow-derived macrophages (BMM) were treated for 24 h with the PORCN 
inhibitor (IWP-L6) or left untreated (control), infected with T. cruzi Tps and assayed for p-CaMKII and NFATc1 expression at 24 h pi. Ionomycin-activated BMM 
(20 min, 1 µM) were used as a positive control. In panels (a,B,D,e), a representative Western blot and the ratio of protein expression to β-actin are shown. 
The results are expressed as the average of three independent experiments ± SEM. Abbreviation: AU, arbitrary units (*P < 0.05; **P < 0.01; ***P < 0.001;  
and ****P < 0.0001).
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Then, we studied whether the inhibition of canonical Wnt 
signaling regulates macrophages function by modulating the 
secretion of pro-inflammatory and anti-inflammatory cytokines. 
Figure  6A shows that inhibition of Wnt/β-catenin  signaling 
induced the secretion of the pro-inflammatory cytokines IFN-γ, 
IL-12, IL-6, and TNF while inhibited the production of TGF-β 
(Figure 6A; Table S1 in Supplementary Material), an effect that 
correlates with the control of parasite replication observed in 
iCRT14-, CCT036477-, or IWP-L6-treated BMM (Figures 5A,B). 
In addition, canonical signaling activation using LiCl or BIO 
induced a slightly upregulation of TGF-β while only LiCl increased 
IL-10 production by T. cruzi-infected BMM (Figure 6A).
Nitric oxide production is counteracted by the expression of 
arginase, an enzyme that competes with iNOS for l-arginine that 
leads to l-ornithine and urea production (47). T. cruzi antigens 
can upregulate arginase activity with this type of activation profile 
associated with the ability to promote the intracellular growth 
of T. cruzi (48). Interestingly, although the pharmacological 
inhibition of Wnt/β-catenin pathway did not affect NO produc-
tion (Figure 6B), the treatments with CCT036477 and IWP-L6 
significantly downregulated arginase activity in infected BMM 
(Figure 6C).
Because IDO activity is also critical for the control of T. cruzi  
amastigote growth in macrophages (7–9), we analyzed the effect 
of the inhibition of Wnt/β-catenin signaling on the activity and 
expression of IDO and their role in the intracellular parasite 
replication control. The inhibition of both β-catenin-responsive 
gene transcription as well as Wnt secretion induced upregulation 
of IDO expression and activity in infected BMM (Figures 6C,D). 
Remarkably, the inhibitory effect of intracellular amastigote 
growth induced by pharmacological inhibitors of the Wnt/β-
catenin pathway was reversed when IDO activity was blocked 
using 1-MT (Figure 6E). In addition, as it was previously dem-
onstrated, 1-MT exacerbated the intracellular parasite replication 
in untreated BMM (Figure  6E). Taken together, these results 
demonstrated that pharmacological inhibition of Wnt/β-catenin 
pathway activates macrophages to fight against T. cruzi.
In Vivo inhibition of Wnt signaling 
improves the resistance to  
T. cruzi infection
Next, we evaluated whether the inhibition of Wnt proteins secre-
tion in vivo would result in the control of the parasite load. Five 
FigUre 5 | The activation of Wnt signaling pathway promotes the replication of Trypanosoma cruzi in macrophages. Bone marrow-derived macrophages (BMM) 
were treated for 24 h with β-catenin activators (LiCl or BIO), specific β-catenin transcriptional inhibitors (iCRT14 and CCT036477), PORCN inhibitor (IWP-L6), or IFNγ 
plus LPS as BMM activation control. Then, the cells were infected with trypomastigotes of T. cruzi, and intracellular parasites were counted by immunofluorescence 
assay. (a) A representative field for each group is shown (2,000×). PBS or DMSO was used as vehicle for LiCl or iCRT14, CCT036477, and IWP-L6, respectively. 
MeBIO was used as control of BIO treatment. (B) The number of intracellular amastigotes was determined by confocal microscopy. Bars represent relative units, 
calculated by dividing number of intracellular parasites (n/200 cells) in differentially treated cultures by number of intracellular parasites (n/200 cells) in the 
corresponding vehicle-treated cultures. (c) Lactate dehydrogenase (LDH) levels were determined in the culture supernatant of uninfected (NI) or differentially 
treated infected BMM at 24 h post-infection. (D) Effect of IWP-L6 treatment on β-catenin activation. Accumulation and nuclear translocation of β-catenin in 
untreated (control), IFNγ plus LPS- or IWP-L6-treated T. cruzi-infected BMM was calculated as described in Section “Materials and Methods.” A representative 
field for each group is shown (1,200×). Bars in panels (B–D) represent averages ± SEM from three (c) or four (B,D) independent experiments (*P < 0.05; 
**P < 0.01; ***P < 0.001; and ****P < 0.0001).
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days after T. cruzi infection with a lethal dose 50 (DL50) of Tps, 
the mice were treated every 3  days with IWP-L6 (Figure  7A). 
The dose of IWP-L6 used has been previously assayed to examine 
the effect of Wnt proteins in an experimental model of cancer (49). 
As expected, in vivo IWP-L6 treatment could maintain inhibited 
both Wnt/β-catenin as well as Wnt/Ca+2 signaling pathways 
until 18 days pi, as denoted by the lack of β-catenin or NFATc1 
accumulation in PM from treated versus control mice (Figure 
S2 in Supplementary Material). Mice infected with T. cruzi and 
injected with vehicle presented high levels of parasitemia, causing 
death of ~50% of mice between 18 and 30 days pi (Figure 7B). 
By contrast, although only four doses of IWP-L6 were given, 
100% of treated mice survived to acute infection and displayed 
lower parasitemia than control mice during the acute phase of the 
infection (Figure 7C). In addition, IWP-L6-treated mice showed 
significantly lower parasite load in liver and heart than control 
mice during the chronic phase of the disease (Figure 7D).
DiscUssiOn
Given that during the acute phase of T. cruzi infection macrophages 
can act as host cells for the parasites as well as effector cells in the 
early anti-parasitic immune response, the targeting of specific 
signaling pathways in macrophages could modulate its response 
FigUre 6 | Pharmacological inhibition of Wnt pathway enhances anti-Trypanosoma cruzi activity of macrophages. Bone marrow-derived macrophages 
(BMM) were treated for 24 h with β-catenin activators (LiCl or BIO), specific β-catenin transcriptional inhibitors (iCRT14 and CCT036477), IWP-L6, 1-MT, 
IFNγ plus LPS or vehicle before being infected with T. cruzi trypomastigotes. (a) Cytokine levels assayed in 24 h post-infection (pi)-supernatants 
represented as Index obtained by dividing the cytokine release of inhibitors/activators-treated BMM for the cytokine release of the corresponding vehicle-
treated BMM. The bars represent averages ± SEM from three independent experiments. (B) Nitrite concentration in 24 h pi-supernatant. (c) Arginase and 
indoleamine 2,3-dioxygenase (IDO) activity assayed in 24 h pi-cell (D) IDO expression. One representative experiment out of three performed for each 
condition is shown. The ratio of protein expression to β-actin is shown, and the results are expressed as the average of three independent experiments 
± SEM. Abbreviation: AU, arbitrary units. Data points of nitric oxide (NO) concentrations, arginase, and IDO activity represent means ± SEM of data 
pooled from three cultures of the same experiment. All data are from one experiment representative of three in total. (e) Number of intracellular amastigotes 
determined by confocal microscopy at 72 h pi. The bars represent relative units, calculated as described in Figure 5B (*P < 0.05; **P < 0.01; ***P < 0.001; 
and ****P < 0.0001).
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to restrict parasite replication and instruct an appropriate adaptive 
immune response. In recent years, it has become apparent that Wnt 
signaling pathway, known for its essential participation in embry-
onic development and tissue homeostasis, exerts immunomodula-
tory functions during inflammation and infection.
In this study, we have demonstrated that early after the 
recognition of T. cruzi by innate immune receptors in BMM, 
β-catenin was activated and Wnt3a, Wnt5a, some Fzd recep-
tors as well as target genes of Wnt/β-catenin pathway as Axin1, 
Wisp1, and Ccnd1 were upregulated. Subsequently to canonical 
pathway activation, Wnt/Ca+2 pathway was activated; since we 
have demonstrated an Wnt proteins-dependent upregulated of 
p-CaMKII-Thr286 and activated NFATc1 expression after infec-
tion. Many studies have demonstrated that T. cruzi utilize the 
host Ca+2 signaling to establish the infection (50) and several 
mechanisms have been proposed to explain the intracellular 
Ca+2 influx that occurs during T. cruzi infection (51). In addi-
tion, Kayama et al. (52) have reported that NFATc1 is activated 
in response to T. cruzi infection in a TLR-independent manner, 
but the critical molecules and signaling pathways that lead to 
NFATc1 activation during T. cruzi infection have not yet been 
identified. Wnt3a and Wnt5a are more commonly associated with 
canonical and non-canonical Wnt signaling, respectively (19). 
However, Wnt5a can also activate discrete β-catenin signaling 
(53, 54), and recent reports have suggested that the activity of 
Wnt ligands and their binding to Fzd receptors depend on the 
cellular context; therefore, Wnt and Fzd proteins cannot be 
rigorously subdivided according to the pathways they induce 
(55). Thus, considering that we found that T. cruzi infection-
induced β-catenin, p-CaMKII-Thr286, and activated NFATc1 
upregulation were suppressed by IWP-L6 treatment, these results 
suggest that both Wnt3a and Wnt5a proteins, and others Wnt 
proteins not evaluated in this paper, could be the responsible 
for the activation and maintenance of both canonical and non-
canonical signaling pathways during T. cruzi infection which 
allows the parasite to spread in the host.
Resistance to T. cruzi infection has been associated with 
the capacity of NK  cells and T  lymphocytes to generate IFN-γ 
which can, in turn, activate macrophages to kill the obligate 
intracellular amastigote form of T. cruzi. The trypanocidal 
activity of pro-inflammatory cytokines-activated macrophages 
is mediated at least by the upregulation of the enzymes iNOS 
and IDO which lead to the production of NO and kynurenines, 
respectively (5–9, 56). On the other hand, susceptibility to infec-
tion is associated with the production of IL-10 and transforming 
growth factor beta (TGF-β) (5, 56). Here, we have demonstrated 
that while the activation of Wnt/β-catenin pathway did not 
promote the intracellular parasite replication, the treatments of 
macrophages with specific inhibitors of β-catenin transcriptional 
activity or the inhibition of Wnt proteins secretion were able to 
inhibit the parasite replication by modifying macrophages activ-
ity. Inhibition of Wnt signaling pathway enhanced production of 
the pro-inflammatory cytokines IFN-γ, IL-12, TNF and IL-6 and 
suppressed production of TGF-β, results that are in agreement 
FigUre 7 | In vivo inhibition of Wnt signaling improves the resistance to Trypanosoma cruzi infection. (a) B6 mice infected with 5,000 T. cruzi trypomastigotes 
were treated with IWP-L6. Vehicle-treated mice were used as control. (B) Parasitemia. Results are means ± SD of 5–6 animals/group and are representative of 
three independent experiments. (c) Survival rate. Data are representative of one of three independent experiments. (D) Relative amount of T. cruzi satellite DNA 
in heart and liver from 180-day T. cruzi-infected IWP-L6 and control mice. Murine GAPDH was used for normalization. Data are shown as mean ± SD of triplicates 
(control, n = 4; IWP-L6, n = 6) mice per group (*P < 0.05; **P < 0.001; and ****P < 0.0001).
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with previous reports showing that the activation of the canoni-
cal pathway in macrophages and DC controls the inflammatory 
response (28). In addition, these treatments induced down-
regulation of arginase activity, an enzyme that counteracts iNOS 
activity, but failed to upregulate iNOS activity, suggesting that the 
resulting treated-macrophages do not fully fit in the classically 
activated/inflammatory macrophage phenotype. Interestingly, 
and despite the fact that there is a close relationship between the 
activation of the Wnt/β-catenin pathway and the induction of 
IDO and vice versa (27, 57, 58), in our experimental model the 
inhibition of β-catenin-induced transcription or Wnt proteins 
secretion upregulated IDO expression and activity. In addition, 
IDO activity proved to be critical for the control of T. cruzi repli-
cation in BMM, as denoted by the recovery of T. cruzi replication 
observed in cultures where the inhibitors were combined with 
1-MT. Expression of IDO and activation of β-catenin within mac-
rophages and DC under tolerogenic conditions are particularly 
important mechanisms that limits inflammation within the gas-
trointestinal tract and tumor cell microenvironment (28, 59). The 
IDO promoter has been shown to exhibit LEF-1 binding sites, and 
kynurenine and quinolinic acid, produced by IDO activity, can 
activate the Wnt/β-catenin pathway (60, 61). However, as IDO 
gene expression is induced not only in tolerogenic conditions but 
also by IFNs and TNF during inflammatory conditions (62, 63), 
in our experimental settings the upregulation of IDO could be 
induced by the milieu of pro-inflammatory cytokines generated 
in inhibitors-treated T. cruzi-infected macrophages. Thus, our 
results suggest that the anti-T. cruzi activity of inhibitor-treated 
macrophages is due to the production of pro-inflammatory 
cytokines-inducible antimicrobial molecules, with IDO being 
one of the most important.
In summary, in this study, we have revealed a new signaling 
pathway that is activated by the interaction between protozoan 
parasites and host innate immunity. In this context, it is well 
founded that T. cruzi infection activates a plethora of signaling 
pathways that ultimately regulate the immune mediators to 
determine the modulation of a defined set of effector functions 
in macrophages and thus establishes a conceptual framework 
for the development of novel therapeutics.
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